The increase in other operating expenses is primarily comprised of an investment in our outpatient electronic medical record systems, along with travel expenses returning to pre-pandemic levels.

Feb 24, 2023 / CEO / receipt, needs a key / Robert Ortenzio, CEO | earnings call 2023-02-24 | transcript fa3db51f-0d79-404d-be55-2b7305245c86 | chars 9643-9837 | segment 9

Consentra experienced a 1% improvement in their salary, wage, and benefit-to-revenue ratio from prior year Q2 and remained consistent with Q1. The reduction in adjusted EBITDA margin from prior year was primarily a result of increased lab and medical supply costs in addition to travel expense returning to normal.

Aug 5, 2022 / CEO / receipt, needs a key / Robert Ortenzio, CEO | earnings call 2022-08-05 | transcript fd9fafa7-d0f6-4bbb-9ec7-62135844642a | chars 9998-10312 | segment 10

Other operating expense to revenue ratio increased by 9% over prior year Q2, mainly due to marketing and travel costs returning to pre-pandemic levels.

Aug 5, 2022 / CEO / receipt, needs a key / Robert Ortenzio, CEO | earnings call 2022-08-05 | transcript fd9fafa7-d0f6-4bbb-9ec7-62135844642a | chars 11439-11590 | segment 11